8-K: Amylyx Q3 2025: Avexitide Trial Update & Cash Runway Extended

Amylyx Pharmaceuticals reported Q3 2025 financial results, updated on its pivotal Phase 3 LUCIDITY trial for avexitide, and extended its cash runway into 2028.

Summary

• Net loss for the third quarter ended September 30, 2025, was $34.4 million, or $0.37 per share, a significant improvement compared to a net loss of $72.7 million, or $1.07 per share, for the same period in 2024.
• Cash, cash equivalents, and marketable securities increased to $344.0 million at September 30, 2025, from $180.8 million at June 30, 2025, primarily due to net proceeds of approximately $191 million from a public offering.
• The company's cash runway is now expected to extend into 2028, funding through important milestones including the potential commercial launch of avexitide in 2027, if approved.
• Recruitment for the pivotal Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia (PBH) is now expected to complete in Q1 2026, with topline data anticipated in Q3 2026.
• Early cohort data from the Phase 1 LUMINA trial of AMX0114 in people living with ALS will be presented at the 36th International Symposium on ALS/MND in December 2025.
• Amylyx plans to initiate a focused, pivotal Phase 3 clinical trial for AMX0035 in Wolfram syndrome in the second half of 2026, pending alignment with the FDA.
• Research and development expenses decreased to $19.9 million in Q3 2025 from $21.2 million in Q3 2024, primarily due to decreased spending on AMX0035 for PSP and ALS, offset by increased spending on avexitide in PBH.
• Selling, general, and administrative expenses decreased to $16.2 million in Q3 2025 from $17.8 million in Q3 2024, mainly due to a decrease in consulting, professional services, and other expenses.
• Product revenue for Q3 2025 was $0, a significant decrease from $416 thousand in Q3 2024 and $88.036 million for the nine months ended September 30, 2024.

Sentiment

Score: 5

Explanation: Mixed sentiment. While the company significantly reduced its net loss and extended its cash runway through a capital raise, the complete loss of product revenue and a delay in the key LUCIDITY trial recruitment are significant negative operational developments. The pipeline progress is positive, but the commercial setback is substantial.

Positives

• Net loss significantly reduced to $34.4 million in Q3 2025 from $72.7 million in Q3 2024.
• Cash, cash equivalents, and marketable securities increased to $344.0 million at September 30, 2025, from $180.8 million at June 30, 2025, following a $191 million public offering.
• Cash runway extended into 2028, providing funding through the potential commercial launch of avexitide.
• Avexitide 90 mg once daily demonstrated a 64% least-squares mean reduction (p=0.0031) vs. baseline in Level 2 and Level 3 hypoglycemic events in PBH Phase 2b trial, with a favorable safety profile.
• AMX0035 in Wolfram syndrome showed stabilization or improvement across key clinical measures in the Phase 2 HELIOS trial, with sustained effects at Week 48.
• AMX0114 received FDA Fast Track designation in June 2025 for ALS.
• Research collaboration with Gubra A/S for a novel long-acting GLP-1 receptor antagonist continues to show encouraging proof-of-concept data.

Negatives

• Product revenue for Q3 2025 was $0, a significant decline from $416 thousand in Q3 2024 and $88.036 million for the nine months ended September 30, 2024.
• Recruitment completion for the pivotal Phase 3 LUCIDITY trial of avexitide was delayed from previous estimates, now expected in Q1 2026.

Risks

• The success, cost, and timing of Amylyx's program development activities are uncertain.
• Amylyx's ability to execute on its regulatory development plans and expectations regarding the timing of results from data announcements and initiation of clinical studies may vary.
• Amylyx's ability to fund operations is subject to risks, including the impact of global macroeconomic uncertainty, geopolitical instability, and public health events.
• Risks and uncertainties are also detailed in Amylyx's United States Securities and Exchange Commission (SEC) filings, including the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings.

Future Outlook

The company expects to complete recruitment for the pivotal Phase 3 LUCIDITY trial in Q1 2026, with topline data anticipated in Q3 2026, and a potential commercial launch of avexitide in 2027, if approved. They also plan to initiate a pivotal Phase 3 trial for AMX0035 in Wolfram syndrome in the second half of 2026, pending FDA alignment. The cash runway is projected to extend into 2028, covering these key development and potential commercialization milestones.

Management Comments

• "Entering the final months of 2025, we are focused on execution as we head toward a transformative year in 2026, with topline data expected from the pivotal Phase 3 LUCIDITY trial."
• "We continue to advance our lead asset avexitide, an investigational, first-in-class inhibitor of GLP-1 receptor activity with FDA Breakthrough Therapy Designation."
• "We continue to see high participant interest and broad engagement across LUCIDITY clinical trial sites, reflecting the significant unmet need for PBH across the U.S."
• "Based on our most recent projections of the trial enrollment rate, we expect completion of recruitment in Q1 2026, with topline data expected in Q3 2026. Our previous estimates assumed a ramp in the enrollment rate at this stage of the trial, but we have seen more of a steady enrollment rate in the last few weeks."
• "Timing remains unchanged for the potential launch of avexitide, if approved, and we are executing on plans to be launch ready in 2027."
• "Additionally, we are excited to share early cohort data from the ongoing Phase 1 LUMINA trial of AMX0114 in people living with ALS at the 36th International Symposium on ALS/MND in December."
• "We expect to have cash runway into 2028, which funds us through important milestones, including the potential launch of avexitide, if approved."
• "Our team remains focused on execution to deliver meaningful innovation for people living with endocrine and neurodegenerative diseases."

Industry Context

Amylyx operates in therapeutic areas with significant unmet medical needs, specifically endocrine and neurodegenerative diseases. Post-bariatric hypoglycemia (PBH), affecting an estimated 8% of bariatric surgery patients (approximately 160,000 people in the U.S.), currently lacks approved therapies, presenting a substantial market opportunity for avexitide. Similarly, ALS and Wolfram syndrome represent conditions with high unmet needs, positioning Amylyx's pipeline assets (AMX0114 and AMX0035) to address critical gaps in treatment. The company's focus on GLP-1 receptor activity for PBH aligns with broader industry interest in GLP-1 pathways for metabolic disorders.

Comparison to Industry Standards

• The 64% reduction in Level 2 and Level 3 hypoglycemic events for avexitide in PBH Phase 2b trials is a strong signal, particularly given the absence of approved therapies for PBH, positioning avexitide favorably against a non-existent standard of care.
• The FDA Breakthrough Therapy Designation for avexitide in PBH and congenital hyperinsulinism, and Fast Track designation for AMX0114 in ALS, indicate regulatory recognition of the potential for these therapies to address serious conditions with unmet needs, aligning with expedited review pathways for innovative treatments in the biotech sector.
• The extension of the cash runway into 2028 through a public offering is a common and necessary strategy for biotechnology companies to fund capital-intensive late-stage clinical development and commercialization efforts, consistent with industry practices for managing drug development financing.

Stakeholder Impact

• Shareholders: The capital raise diluted existing shares but significantly extended the cash runway, reducing immediate financing risk. The delay in the LUCIDITY trial and the loss of product revenue could impact investor confidence and share price. Positive clinical data from pipeline assets could provide future upside.
• Patients (PBH, ALS, Wolfram Syndrome): Continued progress in clinical trials for avexitide, AMX0114, and AMX0035 offers hope for new treatment options for conditions with high unmet needs. The delay in LUCIDITY recruitment means a longer wait for potential avexitide approval.
• Employees: The company's focus on pipeline execution and extended cash runway provides stability, but the shift away from a commercial product might imply internal restructuring or reallocation of resources.
• Creditors: Extended cash runway into 2028 reduces short-to-medium term liquidity concerns.

Next Steps

• Present early cohort data from Phase 1 LUMINA clinical trial of AMX0114 in ALS at the 36th International Symposium on ALS/MND in December 2025.
• Make a decision on a potential development candidate for the Gubra A/S collaboration in the next few months.
• Initiate IND-enabling studies for the Gubra A/S collaboration candidate, pending nomination.
• Complete recruitment for the pivotal Phase 3 LUCIDITY trial in Q1 2026.
• Present biomarker data from the LUMINA trial at a medical meeting in H1 2026.
• Anticipate topline data from the Phase 3 LUCIDITY trial in Q3 2026.
• Initiate a focused, pivotal Phase 3 clinical trial for AMX0035 in Wolfram syndrome in H2 2026, pending FDA alignment.
• Prepare for potential commercial launch of avexitide in 2027, if approved.

Key Dates

Recommendation

The company faces a significant challenge with the complete loss of product revenue, indicating a major commercial setback. However, the successful capital raise has significantly bolstered the cash position, extending the runway into 2028, which is crucial for a biotech in clinical development. The pipeline shows promise with avexitide in Phase 3 for PBH (a condition with no approved therapies), AMX0114 for ALS with Fast Track designation, and AMX0035 for Wolfram syndrome. The delay in LUCIDITY trial recruitment is a concern, but the overall clinical progress and strong cash position warrant a "hold" rather than a "sell" for investors willing to wait for key pipeline readouts in 2026 and 2027. The stock is speculative, but the extended runway provides time for the pipeline to mature.

Keywords

Amylyx Pharmaceuticals, AMLX, Q3 2025, financial results, avexitide, post-bariatric hypoglycemia, PBH, LUCIDITY trial, AMX0114, ALS, LUMINA trial, AMX0035, Wolfram syndrome, GLP-1 receptor antagonist, clinical trials, biotechnology, pharmaceutical, neurodegenerative, endocrine diseases, cash runway, public offering